The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab

The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) Jg. 44; H. 7; S. 912 - 920
Hauptverfasser:	Marty, Michel, Pivot, Xavier
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Oxford Elsevier Ltd 01.05.2008 Elsevier
Schlagworte:	Angiogenesis Angiogenesis Inhibitors Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Anthracyclines Anthracyclines - administration & dosage Antibodies, Monoclonal Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Breast cancer Breast Neoplasms Breast Neoplasms - drug therapy Clinical Trials, Phase III as Topic Female Hematology, Oncology and Palliative Medicine Humans Immunology Life Sciences Medical sciences Monoclonal antibody Neoplasm Metastasis Neovascularization, Pathologic Neovascularization, Pathologic - prevention & control Paclitaxel Paclitaxel - administration & dosage Pharmacology. Drug treatments Taxoids Taxoids - administration & dosage Tumors Tyrosine kinase inhibitor Vascular endothelial growth factor (VEGF) Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A - antagonists & inhibitors Angiogenesis Breast cancer Monoclonal antibody Tyrosine kinase inhibitor Vascular endothelial growth factor (VEGF) Bevacizumab Antineoplastic agent Breast disease Enzyme Transferases VEGF Pharmacology Malignant tumor Metastasis Mammary gland diseases Cancerology Vascular endothelium growth factor Treatment Advanced stage Inhibitor Neovascularization Antiangiogenic agent Protein-tyrosine kinase Vascular endothelial growth factor Cancer
ISSN:	0959-8049, 1879-0852
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!